Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals CEO discusses progress with across clinical programs. https://lnkd.in/eEFaAafC

Hemogenyx Pharmaceuticals outlines significant progress with HEMO-CAR-T in 2023 https://lnkd.in/dPMRFCw6

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) chair Marc Feldmann, in the company’s final results statement, described the year as a “period was a vital one in the progression of the company.” During the year the junior #biopharmaceutical group, which is developing new therapies and treatments for blood #diseases, raised capital on a number of occasions to support this progress. More at #Proactive #ProactiveInvestors http://ow.ly/2mJ8105qMU6

In a recent article, I said at least 20 micro-cap life sciences stocks were waiting to pop once interest returned to the sector. Investors can now add Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) to the watch list after it pulled off the near impossible by raising $4.2 million at a time when investors have largely gone into hibernation. More at #Proactive #ProactiveInvestors http://ow.ly/xrHs105oWvH #LSE #OTC #HEMO #HOPHF

Hemogenyx Pharmaceuticals (LSE:HEMO) CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones. Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. #LSE #HEMO Watch at #Proactive #ProactiveInvestors https://lnkd.in/eDSFn_4M

ICYMI: Hemogenyx Pharmaceuticals now has a green light to go forward with its plans for a phase 1 clinical trial for HEMO-CAR-T. #leusm #AcuteMyeloidLeukemia Read more: https://lnkd.in/emgn9GE2

 Hemogenyx Pharmaceuticals has received a green light from the US Food and Drug Administration (FDA) to proceed with a Phase I clinical trial for its chimeric antigen receptor (CAR) T-therapy, designed to combat acute myeloid leukaemia (AML) in the United States.   https://lnkd.in/dTuXQJey #fdaapproval #unitedstates #america #healthcarenews #trendingnews #medicalnews #worldnews

Roast News Service - RNS - 9th February 2024                           #BZT #PREM #BEN #OCTP #PAT #HEMO #RENX Bezant Resources PlcPremier African MineralsBens Creek Group PLcOxford Cannabinoid Technologies Holdings PlcPanthera Resources PLCHemogenyx PharmaceuticalsRenalytix

Hemogenyx Pharma Plc - FDA Consents to Phase I Trials of HEMO-CAR-T Hemogenyx Pharmaceuticals #LSE #HEMO #Pharmaceuticals